Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction
Open Access
- 6 August 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 106 (6) , 659-665
- https://doi.org/10.1161/01.cir.0000024408.81821.32
Abstract
Background— Despite the use of aspirin, reocclusion of the infarct-related artery occurs in ≈30% of patients within the first year after successful fibrinolysis, with impaired clinical outcome. This study sought to assess the impact of a prolonged anticoagulation regimen as adjunctive to aspirin in the prevention of reocclusion and recurrent ischemic events after fibrinolysis for ST-elevation myocardial infarction.Keywords
This publication has 24 references indexed in Scilit:
- The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: The ASSENT PLUS studyClinical Cardiology, 2001
- Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapyThe American Journal of Cardiology, 1996
- Reocclusion: The flip side of coronary thrombolysisJournal of the American College of Cardiology, 1996
- Adverse long-term effects of reocclusion after coronary thrombolysisJournal of the American College of Cardiology, 1995
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarctionPublished by Elsevier ,1992
- Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: A meta-analysisJournal of the American College of Cardiology, 1992
- Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.Heart, 1992
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985